Diabetes Translational Research Core

糖尿病转化研究核心（DTRC）服务于DRC的一项关键使命，即提供 将基于实验室的糖尿病发现和设备技术引入临床所需的基础设施 以改善护理，减少糖尿病并发症，并最终减少 糖尿病在整个生命周期。此外，DTRC还帮助耶鲁大学成为世界上最好的大学之一。 糖尿病临床和转化研究的机构，如许多 我们的研究人员在当前资助期间发表的出版物。DTRC支持前沿技术，基础广泛 近年来，转化研究计划已扩大到包括以下领域： 糖尿病技术（CGM和闭环胰岛素输送系统）;功能性MRI、MR光谱和 PET研究;和T1 D的新免疫疗法，以及参与T1和T2 D登记和新的 NIH申办的多中心临床试验。耶鲁大学的翻译研究组合的显着扩张 DTRC和耶鲁分析科学中心之间的协同作用也使之成为可能 （YCAS），耶鲁大学临床研究中心（YCCI）和其他耶鲁资源，支持翻译 research.研究中心在下一个资助期内的目标是：提供专门的研究 基础设施（训练有素的人员、设备使用、实验室资源、研究设施）以及 研究人员进行复杂的糖尿病相关研究以及临床试验所需的培训， 糖尿病和相关的代谢紊乱。2.与YCAS和耶鲁联合数据分析合作 小组（联合灾害管理和评估小组），以支持规程和赠款的制定;数据管理和数据分析;以及利用 耶鲁大学的电子健康记录（EHR），以提高DRC研究人员识别和登记患者的能力 并分析有关医疗保健服务绩效的数据。3.与YCCI合作， IRB文件准备中的DRC研究者;预算谈判;临床试验协议; clinicaltrials.gov 登记;以及在T1 D交换和儿科糖尿病联盟中招募糖尿病患者 T2 D登记研究。DTRC支持的调查涵盖了糖尿病相关疾病的整个范围 (e.g., T1和T2 D和肥胖）;涉及整个生命期的人类受试者（即，儿科学和医学）， 测试新药物、设备和行为干预的有效性和安全性;并描述潜在的 代谢改变的基础和大脑在预防低血糖和饮食失调中的作用。 DTRC的强大领导力与我们的高级糖尿病专家的国际地位相结合 调查人员和不断涌入的聪明和热情的年轻调查人员提供了保证， 在下一个资助期内，该中心将继续保持高水平的表现。

The Diabetes Translational Research Core (DTRC) serves a key mission of the DRC; namely, to provide the infrastructure needed to bring laboratory based diabetes discoveries and device technologies into the clinical setting so as to improve care, diminish diabetes complications and ultimately diminish the prevalence of diabetes across the life-span. Moreover, the DTRC has assisted in establishing Yale as one of the premier institutions in the world for clinical and translational research in diabetes, as illustrated by the many publications by our investigators during the current grant period. DTRC support of cutting edge, broadly based translational research programs has been expanded in recent years to include areas such as advances in diabetes technologies (CGM and closed-loop insulin delivery systems); functional MRI, MR Spectroscopy and PET studies; and new immune-therapeutics for T1D, as well as participation in T1 and T2D Registries and new NIH-sponsored multi-center clinical trials. The remarkable expansion of Yale’s translational research portfolio has also been made possible by the synergy between the DTRC and the Yale Center for Analytic Science (YCAS), the Yale Center for Clinical Investigation (YCCI) and other Yale resources that support translational research. The aims of the DTRC during the next grant period are: 1. To provide specialized research infrastructure (trained personnel, access to equipment, laboratory resources, research facilities) as well as the training needed for investigators to carry out complex diabetes-related studies as well as clinical trials in diabetes and related metabolic disorders. 2. To partner with YCAS and the and the Yale Joint Data Analytics Team (JDAT) to support protocol and grant development; data management and data analyses; and utilization of Yale’s Electronic Health Record (EHR) to enhance DRC investigators’ capacity to identify and enroll patients into studies and to analyze data on health care delivery performance. 3. To partner with the YCCI to support DRC investigators in IRB document preparation; budget negotiations; clinical trial agreements; clinicaltrials.gov registration; and enrollment of diabetes patients in the T1D Exchange and the Pediatric Diabetes Consortium T2D Registries. Investigations supported by the DTRC span the entire range of diabetes related disorders (e.g., T1 and T2D and obesity); involve human subjects over the entire life-span (i.e., pediatrics and medicine), test the efficacy and safety of new drugs, devices and behavioral interventions; and describe the underlying basis of metabolic alterations and the role of the brain in the prevention of hypoglycemia and disorder eating. The strong leadership of the DTRC in combination with the international stature of our senior diabetes investigators and the continuing influx of bright and enthusiastic young investigators provides assurance that the DTRC will continue to perform at a high level during the next grant period.